Clinical Trials Brief | June 29, 2026
This week's five signals cover HHS launching Operation TrialBlazer with an expedited first-in-human IND pilot, FDA's revised substantial evidence draft guidance, CHMP recommending revocation of Tavneos over pivotal trial data integrity, new EMA safety actions for liquid rifampicin and Ixchiq, and AbbVie's agreement to buy Apogee for about $10.9 billion.
HHS launches Operation TrialBlazer, an explicit bid to pull first-in-human trials back to the United States
What changed
On June 22, 2026, HHS unveiled Operation TrialBlazer, a department-wide effort to accelerate clinical research conducted in the United States. FDA's contributions include a proposed Expedited-IND Pilot, clarified CMC expectations for Phase 1 IND submissions, and a revised draft of its substantial evidence guidance. The pilot would create a network of Qualified Research Institutions that advise sponsors on the nonclinical, clinical, and CMC parts of an initial IND while sharing recommendations with FDA through a rolling submission platform. The Federal Register RFI requests comments by July 22. A separate HHS OIG RFI on trial-participant payments has comments due August 24.
Why it matters
The policy rationale is explicit: China overtook the U.S. in global share of Phase 1 trials in 2021. The QRI concept introduces a third party between sponsor and regulator in the IND process, raising practical questions about conflicts of interest, oversight, and what happens when FDA disagrees with a QRI recommendation. The participant-payment RFI could also affect how sites reimburse travel and time, with direct implications for recruitment and retention.
Takeaway
Three comment windows are now open: July 22 for the Expedited-IND Pilot, August 24 for the participant-remuneration RFI, and September 22 for the substantial evidence draft guidance. Academic medical centers and sponsors whose early-phase strategy defaults to ex-U.S. sites have the most at stake in shaping the pilot.
Sources
This item is grounded in the HHS and FDA announcements of June 22, 2026 and the Arnold & Porter advisory of June 24, 2026.
FDA's revised substantial evidence draft guidance makes one pivotal trial plus confirmatory evidence the planning default
What changed
As part of the TrialBlazer package, FDA issued revised draft guidance on demonstrating substantial evidence of effectiveness. The draft describes a single adequate and well-controlled trial with confirmatory evidence as a viable default, while listing related controlled trials, related indications, same-class trials, mechanistic information, early-phase data, and natural-history or registry data as possible sources. It also introduces statistical flexibility and recommends discussing the evidence strategy by the pre-IND meeting and no later than the end of Phase 2. Comments are due September 22, 2026.
Why it matters
A single-trial program leaves no second study to absorb a GCP problem, so conduct quality becomes part of the efficacy argument. FDA also emphasizes representativeness, site selection, protocol adherence, follow-up completeness, missing data, and prespecified sensitivity analyses.
Takeaway
If a program is planning a single pivotal trial, its confirmatory evidence package should be documented before the trial starts. Teams should also assess how much U.S. enrollment is needed to answer FDA's representativeness question.
Sources
This item is grounded in the Arnold & Porter advisory of June 24, 2026, FDA's TrialBlazer fact sheet, and the February 2026 NEJM Sounding Board.
CHMP recommends revoking Tavneos in the EU after a review triggered by data-integrity questions
What changed
At its June 22-25, 2026 meeting, CHMP concluded its review of Tavneos (avacopan), used for severe active GPA and MPA. The committee recommended revoking the EU marketing authorisation because the medicine's benefits are no longer proven to outweigh its risks. EMA said the review assessed new information raising data-integrity questions about the main study supporting the EU authorisation.
Why it matters
The benefit-risk balance fell because the efficacy evidence itself could no longer be relied on, not because a new adverse reaction emerged. This is a clear example of data integrity determining whether a product stays on the market years after approval.
Takeaway
The CHMP opinion is a recommendation; the legally binding step is the European Commission decision that follows. For sponsors, pivotal-trial data integrity is a lifecycle obligation, not only a pre-approval hurdle.
Sources
This item is grounded in EMA's CHMP meeting highlights for June 22-25, 2026 and EMA's Tavneos referral page.
CHMP opens an excipient review of liquid rifampicin and narrows Ixchiq to high-risk people aged 12 and over
What changed
The June CHMP meeting produced two safety actions: an Article 31 review of Rifadin liquid formulations over concerns about diethanolamine, and a recommendation to limit Ixchiq's marketing authorisation to people aged 12 and older at high risk of acquiring chikungunya infection.
Why it matters
The Rifadin review shows that safety referrals are not always about the active substance. Excipient levels sit at the boundary between quality and safety, while the Ixchiq recommendation continues a stepwise narrowing of who should receive the vaccine.
Takeaway
Sponsors using liquid rifampicin in tuberculosis trials should track the referral. Travel-medicine and outbreak-response protocols should be checked against the narrower Ixchiq population once the European Commission decision is issued.
Sources
This item is grounded in EMA's CHMP meeting highlights for June 22-25, 2026 and EMA's Rifadin referral page.
AbbVie agrees to buy Apogee for about $10.9 billion, betting that less frequent dosing is the next differentiator in immunology
What changed
On June 22, 2026, AbbVie and Apogee announced a definitive agreement under which AbbVie will acquire Apogee for $135.11 per share in cash, representing approximately $10.9 billion in equity value. Apogee's lead asset is zumilokibart (APG777), a subcutaneous, half-life-extended monoclonal antibody against IL-13 in development for moderate-to-severe atopic dermatitis.
Why it matters
The strategic thesis is dosing frequency: IL-13 is validated, so differentiation is fewer injections per year rather than a new mechanism. Phase 3 design will need endpoints and patient-reported outcomes that capture convenience and durability, not only EASI response.
Takeaway
Watch how AbbVie structures the zumilokibart Phase 3 program, especially maintenance-dosing arms and durability endpoints. Adding another major sponsor to dermatology is a signal to revisit enrollment assumptions for AD studies planned for 2027.
Sources
This item is grounded in the joint AbbVie-Apogee announcement filed with the SEC on June 22, 2026 and Apogee's second-quarter 2026 report.